Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-01

Clinical Trial Update: Evaluation of Dapagliflozin Taken Twice-daily [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated twice-daily dapagliflozin for Type 2 diabetes; results were posted in November 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Farxiga (dapagliflozin) (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2013-11-01